Capstan Medical Secures $110M for Robotic Heart Valve Trials and Development
Capstan Medical has successfully secured $110 million in a Series C funding round, which is set to propel its advancements in robotic heart valve implant technology[1][2]. This investment round, led by Eclipse and supported by returning investors like Intuitive Ventures and new investors such as Gideon Strategic Partners, will aid in developing Capstan's minimally invasive, robotic-assisted systems aimed at treating mitral and tricuspid valve regurgitation[1][2]. With the funds, Capstan plans to initiate pivotal trials by 2026 and first-in-human trials by early 2025, while also expanding its team to meet these goals[1][2].
References
Explore Further
What specific advantages does Capstan Medical's robotic system offer over current manual heart valve replacement systems?
How does Capstan Medical plan to compete with established market leaders like Abbott and Edwards Lifesciences in terms of technology and market reach?
What challenges might Capstan Medical face in the clinical trials for their robotic heart valve technology scheduled for 2025 and beyond?
In what ways could Capstan Medical's expansion potentially impact the treatment options for aortic valve conditions?
How might Capstan Medical's collaboration with investors like Eclipse and Intuitive Ventures accelerate the timeline for bringing their technology to market?